These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 14610416)

  • 1. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.
    Nanus DM; Milowsky MI; Kostakoglu L; Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Bander NH
    J Urol; 2003 Dec; 170(6 Pt 2):S84-8; discussion S88-9. PubMed ID: 14610416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
    Vallabhajosula S; Smith-Jones PM; Navarro V; Goldsmith SJ; Bander NH
    Prostate; 2004 Feb; 58(2):145-55. PubMed ID: 14716739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
    Milowsky MI; Nanus DM; Kostakoglu L; Sheehan CE; Vallabhajosula S; Goldsmith SJ; Ross JS; Bander NH
    J Clin Oncol; 2007 Feb; 25(5):540-7. PubMed ID: 17290063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
    Bander NH; Trabulsi EJ; Kostakoglu L; Yao D; Vallabhajosula S; Smith-Jones P; Joyce MA; Milowsky M; Nanus DM; Goldsmith SJ
    J Urol; 2003 Nov; 170(5):1717-21. PubMed ID: 14532761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
    Bander NH; Nanus DM; Milowsky MI; Kostakoglu L; Vallabahajosula S; Goldsmith SJ
    Semin Oncol; 2003 Oct; 30(5):667-76. PubMed ID: 14571414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
    Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
    Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
    Bander NH; Milowsky MI; Nanus DM; Kostakoglu L; Vallabhajosula S; Goldsmith SJ
    J Clin Oncol; 2005 Jul; 23(21):4591-601. PubMed ID: 15837970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy.
    Lu SX; Takach EJ; Solomon M; Zhu Q; Law SJ; Hsieh FY
    J Pharm Sci; 2005 Apr; 94(4):788-97. PubMed ID: 15729708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
    Milowsky MI; Nanus DM; Kostakoglu L; Vallabhajosula S; Goldsmith SJ; Bander NH
    J Clin Oncol; 2004 Jul; 22(13):2522-31. PubMed ID: 15173215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.
    Vallabhajosula S; Nikolopoulou A; Jhanwar YS; Kaur G; Tagawa ST; Nanus DM; Bander NH; Goldsmith SJ
    Curr Radiopharm; 2016; 9(1):44-53. PubMed ID: 25771365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.
    Tagawa ST; Beltran H; Vallabhajosula S; Goldsmith SJ; Osborne J; Matulich D; Petrillo K; Parmar S; Nanus DM; Bander NH
    Cancer; 2010 Feb; 116(4 Suppl):1075-83. PubMed ID: 20127956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.
    Morris MJ; Divgi CR; Pandit-Taskar N; Batraki M; Warren N; Nacca A; Smith-Jones P; Schwartz L; Kelly WK; Slovin S; Solit D; Halpern J; Delacruz A; Curley T; Finn R; O'donoghue JA; Livingston P; Larson S; Scher HI
    Clin Cancer Res; 2005 Oct; 11(20):7454-61. PubMed ID: 16243819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
    Pandit-Taskar N; O'Donoghue JA; Beylergil V; Lyashchenko S; Ruan S; Solomon SB; Durack JC; Carrasquillo JA; Lefkowitz RA; Gonen M; Lewis JS; Holland JP; Cheal SM; Reuter VE; Osborne JR; Loda MF; Smith-Jones PM; Weber WA; Bander NH; Scher HI; Morris MJ; Larson SM
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2093-105. PubMed ID: 25143071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Application of a Novel Model System to Study "Active" and "Passive" Tumor Targeting.
    Mukherjee A; Kumar B; Hatano K; Russell LM; Trock BJ; Searson PC; Meeker AK; Pomper MG; Lupold SE
    Mol Cancer Ther; 2016 Oct; 15(10):2541-2550. PubMed ID: 27486224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
    Pandit-Taskar N; O'Donoghue JA; Durack JC; Lyashchenko SK; Cheal SM; Beylergil V; Lefkowitz RA; Carrasquillo JA; Martinez DF; Fung AM; Solomon SB; Gönen M; Heller G; Loda M; Nanus DM; Tagawa ST; Feldman JL; Osborne JR; Lewis JS; Reuter VE; Weber WA; Bander NH; Scher HI; Larson SM; Morris MJ
    Clin Cancer Res; 2015 Dec; 21(23):5277-85. PubMed ID: 26175541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
    Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR
    Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of monoclonal antibodies in the imaging of prostate cancer.
    Yao D; Trabulsi EJ; Kostakoglu L; Vallabhajosula S; Joyce MA; Nanus DM; Milowsky M; Liu H; Goldsmith SJ
    Semin Urol Oncol; 2002 Aug; 20(3):211-8. PubMed ID: 12215974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
    Richman CM; Denardo SJ; O'Donnell RT; Yuan A; Shen S; Goldstein DS; Tuscano JM; Wun T; Chew HK; Lara PN; Kukis DL; Natarajan A; Meares CF; Lamborn KR; DeNardo GL
    Clin Cancer Res; 2005 Aug; 11(16):5920-7. PubMed ID: 16115934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.
    David KA; Milowsky MI; Kostakoglu L; Vallabhajosula S; Goldsmith SJ; Nanus DM; Bander NH
    Clin Genitourin Cancer; 2006 Mar; 4(4):249-56. PubMed ID: 16729907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
    Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
    J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.